• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Proactive news headlines including Tiziana Life Sciences, BetterLife Pharma, Silvercorp Metals and Mind Medicine

    2/2/21 10:48:35 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLSA alert in real time by email

    New York, Feb. 02, 2021 (GLOBE NEWSWIRE) -- - Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) hails positive results from Brazil coronavirus study of breakthrough nasally-administered antibody treatment click here

    - BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) files patent protection for its newest compound TD-010 to treat anxiolytic-use disorder click here

    - Heritage Cannabis Holdings Corp (CSE:CANN) (OTCQX:HERTF) (FRA:2UE) files a preliminary prospectus for an upcoming equity financing click here

    - Mirasol Resources Ltd (CVE:MRZ) (OTCPINK:MRZLF) (FRA:M8R) commences new 2,700 metre drill program at Virginia silver project in Argentina click here

    - HempFusion Wellness Inc (TSX:CBD.U) (FRA:8OO) announces exclusive partnership with racing team Loenbro Motorsports for 2021 season click here

    - Mind Medicine (MindMed) Inc (NEO:MMED) (OTCQB:MMEDF) (FRA:MMQ) unveils changes at the top as it advances its psychedelic medicine strategy click here

    - Nabis Holdings Inc (CSE:NAB) (OTCMKTS:NABIF) (FRA:A2PL) provides update on its Arizona cannabis operations; settles lawsuit click here

    - Silvercorp Metals Inc (TSX:SVM) (NYSEAMERICAN:SVM) (FRA:S9Y) subsidiary acquires La Yesca silver project in Mexico click here

    - Fury Gold Mines Limited (TSE:FURY) (NYSEAMERICAN:FURY) (FRA:AUN1) aims to kick off 25,000m of drilling at Homestake Ridge gold-silver project this summer click here

    - African Gold Group Inc (CVE:AGG) (OTCMKTS:AGGFF) (FRA:3A61) says latest drilling at flagship Kobada gold project augurs well for expanding resources click here

    About Proactive

    With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors.

    Proactive’ s platform delivers the right message to the right audience, digitally and in real time, leveraging a range of media, investment research, digital investor targeting and website development services to support over 1,000 fast-growing companies globally.

    Proactive’s network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

    •           Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.

    •           We syndicate our content to hundreds of mainstream and specialist news sites that expand our reach into networks that can be difficult for press releases to penetrate.

    •           We custom build corporate websites from the ground up, empowering clients and their brands with a modern online presence and the latest insight on effective SEO strategy.

    •           Our news coverage ranks high on the world’s most popular search platforms, and we can further amplify online presence and outreach with sophisticated digital investor targeting.    

    •           We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.

    For more information on how Proactive can help you make a difference, email us at [email protected]


    Get the next $TLSA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zacks Investment Research initiated coverage on Tiziana Life Sciences with a new price target

    Zacks Investment Research initiated coverage of Tiziana Life Sciences with a rating of Not Rated and set a new price target of $7.50

    4/12/21 11:57:17 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

    BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston, Massachusetts. MSA is a rare, rapidly progressive neurodegenerative disorder affecting the body's movement, balance, and autonomic functions. Classified as an orphan disease

    8/14/25 8:30:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

    NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atrophy is an unmet medical need as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease. The Phase 2a study (ClinicalTrials.gov Identifier: N

    8/11/25 9:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

    NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced compelling immunologic findings from the treatment of a moderate Alzheimer's Disease (AD) patient with intranasal foralumab. Transcriptional analysis of white blood cells before and after foralumab therapy revealed profound immune modulatory effects. Significant changes were observed in CD4 cells, CD8 cells, and monocytes, underscoring the broad impact of nasal foralumab on immune ce

    7/21/25 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    SEC Filings

    View All

    SEC Form 6-K filed by Tiziana Life Sciences Ltd.

    6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

    8/14/25 8:30:01 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Tiziana Life Sciences Ltd.

    6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

    8/11/25 9:00:02 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Tiziana Life Sciences Ltd.

    6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

    7/21/25 7:00:12 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Leadership Updates

    Live Leadership Updates

    View All

    Tiziana Life Sciences Appoints New Chief Executive Officer

    NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building in

    8/19/24 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

    NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious "Giants of MS" award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multipl

    5/30/24 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

    Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates. Dr. Clementi brings with

    8/23/23 10:30:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tiziana Life Sciences Ltd.

    SC 13G - Tiziana Life Sciences Ltd (0001723069) (Subject)

    5/4/22 4:34:27 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Tiziana Life Sciences plc

    SC 13D - Tiziana Life Sciences Ltd (0001723069) (Subject)

    1/4/22 4:31:31 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Tiziana Life Sciences plc (0001723069) (Subject)

    2/16/21 7:32:16 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Financials

    Live finance-specific insights

    View All

    Tiziana Life Sciences Announces Date of Annual General Meeting 2022

    NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-ge

    12/6/22 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

    NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Sclerosis (SPMS), Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "We look forward to leveraging the exciting clinical and preclinical results from our

    11/10/22 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

    NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. Date:Wednesday, September 8, 2021  Time:4:15 p.m. Eastern Time  Live Call:+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)

    9/7/21 2:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care